Anlon Healthcare Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0l8v5l45l7n3irekrzd4nv2u.pdf

Key Takeaways


Margin Recovery & Profitability

Punitkumar Rasadia: "The cost of material is increased along with the interest rate also is if we are having the cash in hand and we are getting with the lower credit terms, then we are getting the better price that can also be beneficial in increase our PAT and profitability."

CDMO: The Long-Gestation Bet

Punitkumar Rasadia: "I would reiterate that CDMO molecule typically takes a minimum of 3 to 4 years from development to commercial revenue, which is precisely what makes this relationship durable once established."

Expansion & New Business Lines


Cash Flow & Balance Sheet


Product Pipeline & Regulatory Moat

Punitkumar Rasadia: "In this business, registration rather than price is getting factored. A new entrant must build the chemistry file with the DMF and clear customer audits in each jurisdiction before it can even quote. That is what makes our registered supplier status durable."

Revenue Mix & Capacity


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 full-year revenue₹380 crores to ₹400 crores; management stated they are "almost in line with that target"FY27 full year
FY28 full-year revenue₹650 crores to ₹700 crores, based on ongoing expansion projects and existing business with sure-shot customer commitmentsFY28 full year
FY27 EBITDA marginAt least 25%–26% for full-year FY27 results, based on current projections and orders in handFY27 full year
Sustainable EBITDA margin25%–27% consolidated, once remaining price revisions and integration benefits realizeOngoing from FY27
Positive operating cash flowDeliver positive operating cash flow on an annual basisBy end of FY27
CDMO molecule 1 commercial supplyCommercial supply to beginEnd of Q3 FY27 or first month of Q4 FY27
CDMO molecule 1 meaningful revenueSignificant revenue contribution expectedBy Q4 FY28
CDMO molecules 2 and 3 commercializationCommercial supply to beginAfter H1 FY28 (minimum 6–8 months from now)
Rajkot greenfield commissioningCommissioning and revenue contribution to beginCommissioning Q1 FY28; revenue from Q2 FY28
Anlon Medicos first revenueFirst revenue from finished dosage formulationsQ4 FY27 (delayed from Q3 FY27)
Anlon Biologics first revenueFirst revenue from peptides, oligonucleotides, biosimilarsQ4 FY28
Share swap completionFull ownership of Bizotic and Apiqo via allotment and swappingWithin next 8–10 days
DMF filings in FY27~6 DMFs to be filed; 3 by December, remainder by February–MarchFY27
Loxoprofen topical gel approvalDCGI approval expectedAt least Q1 FY28
Apiqo capacity expansion500–600 MTPA expansion completionQ1 FY28
Injectable facility at Anlon MedicosExpansion completionBy end of next year
Medical devices revenue₹70–80 crores revenueWithin next 3 years

Key Metrics

MetricQ2 FY27
Revenue from operations₹105.61 cr, +102.3% YoY and +20.6% QoQ
H1 FY27 revenue from operations₹193.17 cr, +125.9% YoY; exceeded full-year FY26 revenue
EBITDA₹25.24 cr, +84.1% YoY and +61.9% QoQ
EBITDA margin23.9%, +610 bps QoQ from 17.8% in Q1 FY27; raw material cost pass-through effected
H1 FY27 EBITDA margin21.1%
Profit after tax₹17.18 cr, +84.4% YoY
H1 FY27 profit after tax₹25.46 cr, +97.9% YoY
FY27 full-year revenue guidance₹380 cr to ₹400 cr, maintained
FY28 full-year revenue guidance₹650 cr to ₹700 cr, excluding CDMO and medical devices contribution
Consolidated capacity utilization65% to 67%; Anlon standalone at 85% to 86% (optimum)
Installed manufacturing capacity (group)~1,900 to 2,000 MTPA, vs 400 MTPA at parent previously; Rajkot greenfield adding ~1,200 MTPA commissioning Q1 FY28
Net cash used in operating activities (H1 FY27)₹7.94 cr, vs ₹79.44 cr for full-year FY26; working capital outflow reduced materially
Receivable days~123 days annualized (per an analyst's math); credit terms reduced to 90–100 days from 130–140 days
DMFs filed with global authorities21; 4 products commercialized and validated; 3 additional filings planned by December, 2–3 more by Q4 FY27
CDMO molecules under development3 molecules for 2 global innovator companies; first commercial supply delayed to end-Q3 or early Q4 FY27; molecules 2 and 3 commercialization expected after H1 FY28